Mark Scalzo

2.2k total citations · 2 hit papers
10 papers, 1.3k citations indexed

About

Mark Scalzo is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Mark Scalzo has authored 10 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Oncology. Recurrent topics in Mark Scalzo's work include Radiopharmaceutical Chemistry and Applications (9 papers), Prostate Cancer Treatment and Research (9 papers) and Medical Imaging Techniques and Applications (2 papers). Mark Scalzo is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (9 papers), Prostate Cancer Treatment and Research (9 papers) and Medical Imaging Techniques and Applications (2 papers). Mark Scalzo collaborates with scholars based in Australia, Argentina and Singapore. Mark Scalzo's co-authors include Michael S. Hofman, Rodney J. Hicks, John Violet, Price Jackson, Scott Williams, Shahneen Sandhu, Declan G. Murphy, Aravind Ravi Kumar, Amir Iravani and Peter Eu and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Mark Scalzo

10 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

2018 815 citations Michael S. Hofman, John Violet et al. The Lancet Oncology profile →
Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

2018 339 citations John Violet, Price Jackson et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Scalzo Australia	7	1.1k	1.1k	398	117	110	10	1.3k
Aravind Ravi Kumar Australia	11	1.2k 1.1×	1.2k 1.1×	467 1.2×	166 1.4×	116 1.1×	24	1.6k
Stefan Kürpig Germany	15	1.2k 1.1×	1.0k 1.0×	461 1.2×	88 0.8×	97 0.9×	25	1.3k
Sue Ping Thang Singapore	9	1.2k 1.1×	1.3k 1.2×	566 1.4×	172 1.5×	111 1.0×	28	1.7k
Germo Gericke United States	4	1.0k 1.0×	1.2k 1.1×	563 1.4×	190 1.6×	83 0.8×	6	1.6k
Andrei Gafita United States	23	1.5k 1.3×	1.6k 1.5×	373 0.9×	209 1.8×	105 1.0×	93	1.9k
Marcus Bronzel Germany	6	828 0.8×	683 0.6×	288 0.7×	45 0.4×	84 0.8×	12	940
Anna Yordanova Germany	19	1.2k 1.1×	1.1k 1.1×	676 1.7×	122 1.0×	100 0.9×	39	1.6k
Karina Knorr Germany	12	819 0.7×	851 0.8×	290 0.7×	103 0.9×	69 0.6×	29	1.0k
Bao Ho Australia	20	1.2k 1.1×	1.9k 1.8×	228 0.6×	252 2.2×	50 0.5×	42	2.1k
Martina Weineisen Germany	7	742 0.7×	754 0.7×	250 0.6×	52 0.4×	79 0.7×	12	942

Countries citing papers authored by Mark Scalzo

Since Specialization

Citations

This map shows the geographic impact of Mark Scalzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Scalzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Scalzo more than expected).

Fields of papers citing papers by Mark Scalzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Scalzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Scalzo. The network helps show where Mark Scalzo may publish in the future.

Co-authorship network of co-authors of Mark Scalzo

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Scalzo. A scholar is included among the top collaborators of Mark Scalzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Scalzo. Mark Scalzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Ferreira, María del Rosario, et al.. (2024). Changes in cerebral cortex redox status and cognitive performance in short- and long-term high-sucrose diet fed rats. Physiology & Behavior. 290. 114776–114776. 1 indexed citations

Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2022). PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(16_suppl). 5017–5017. 34 indexed citations

Alghazo, Omar, Renu Eapen, Nattakorn Dhiantravan, et al.. (2021). Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).. Journal of Clinical Oncology. 39(6_suppl). TPS264–TPS264. 2 indexed citations

Dhiantravan, Nattakorn, John Violet, Renu Eapen, et al.. (2020). Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. European Urology Focus. 7(2). 234–237. 37 indexed citations

Jackson, Price, Michael S. Hofman, Rodney J. Hicks, Mark Scalzo, & John Violet. (2019). Radiation Dosimetry in ¹⁷⁷Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. Journal of Nuclear Medicine. 61(7). 1030–1036. 84 indexed citations

Hofman, Michael S., John Violet, Rodney J. Hicks, et al.. (2019). Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). 228–228. 7 indexed citations

Hofman, Michael S., John Violet, Rodney J. Hicks, et al.. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. The Lancet Oncology. 19(6). 825–833. 815 indexed citations breakdown →

Violet, John, Price Jackson, Justin Ferdinandus, et al.. (2018). Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of Nuclear Medicine. 60(4). 517–523. 339 indexed citations breakdown →

Hofman, Michael S., John Violet, Shahneen Sandhu, et al.. (2018). High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial. 59. 531–531. 3 indexed citations

10.

Hofman, Michael S., Shahneen Sandhu, Peter Eu, et al.. (2017). Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA. Annals of Oncology. 28. v270–v270. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact